Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Coherus Oncology (CHRS) Cost of Revenue (2019 - 2025)

Coherus Oncology (CHRS) has disclosed Cost of Revenue for 7 consecutive years, with $4.0 million as the latest value for Q4 2025.

  • Quarterly Cost of Revenue rose 47.09% to $4.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.8 million through Dec 2025, up 58.29% year-over-year, with the annual reading at $13.8 million for FY2025, 58.29% up from the prior year.
  • Cost of Revenue hit $4.0 million in Q4 2025 for Coherus Oncology, up from $3.7 million in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $84.6 million in Q4 2023 to a low of $1.4 million in Q1 2024.
  • Historically, Cost of Revenue has averaged $15.5 million across 5 years, with a median of $10.3 million in 2022.
  • Biggest five-year swings in Cost of Revenue: skyrocketed 495.46% in 2023 and later tumbled 96.75% in 2024.
  • Year by year, Cost of Revenue stood at $12.1 million in 2021, then grew by 17.33% to $14.2 million in 2022, then surged by 495.46% to $84.6 million in 2023, then crashed by 96.75% to $2.8 million in 2024, then soared by 47.09% to $4.0 million in 2025.
  • Business Quant data shows Cost of Revenue for CHRS at $4.0 million in Q4 2025, $3.7 million in Q3 2025, and $3.4 million in Q2 2025.